Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1995 2
1996 1
2001 1
2010 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for J. E. cleophas
Your search for J. E. Cleophat retrieved no results
Clinical trials: relevance of correlation between treatment responses.
Cleophas TJ. Cleophas TJ. Eur J Clin Pharmacol. 1996;50(1-2):1-6. doi: 10.1007/s002280050061. Eur J Clin Pharmacol. 1996. PMID: 8739804 Review.
Both designs would seem suitable for approximately zero correlations (e.g. comparison vs baseline or vs placebo under the assumption that the number of placebo responders is negligible....
Both designs would seem suitable for approximately zero correlations (e.g. comparison vs baseline or vs placebo under the assumption …
Beta-blockers and heart failure: meta-analysis of mortality trials.
Cleophas TJ, Zwinderman AH. Cleophas TJ, et al. Int J Clin Pharmacol Ther. 2001 Sep;39(9):383-8. doi: 10.5414/cpp39383. Int J Clin Pharmacol Ther. 2001. PMID: 11563684
This endpoint is important, because if patients die for reasons other than progression of heart failure, e.g. arrhythmias, then alternative antiarrhythmic agents may serve equally well or better than beta-blockers and with fewer side effects. ...
This endpoint is important, because if patients die for reasons other than progression of heart failure, e.g. arrhythmias, then alter …
Treatment of vasospastic disease with prostaglandin E1.
Cleophas AJ, Fennis JF, van't Laar A. Cleophas AJ, et al. Br Med J (Clin Res Ed). 1981 May 2;282(6274):1476. doi: 10.1136/bmj.282.6274.1476-b. Br Med J (Clin Res Ed). 1981. PMID: 6784876 Free PMC article. No abstract available.
Clinical trials: relevance of correlation between treatment modalities.
Cleophas TJ. Cleophas TJ. Int J Clin Pharmacol Ther. 1995 Dec;33(12):670-5. Int J Clin Pharmacol Ther. 1995. PMID: 8963485 Review.
Both designs are suitable for approximately zero correlations (e.g. comparison vs placebo)....
Both designs are suitable for approximately zero correlations (e.g. comparison vs placebo)....
Time-dependent predictors in clinical research, performance of a novel method.
van de Bosch J, Atiqi R, Cleophas TJ. van de Bosch J, et al. Am J Ther. 2010 Nov-Dec;17(6):e202-7. doi: 10.1097/MJT.0b013e3181d5e411. Am J Ther. 2010. PMID: 20393346
In a long-term therapeutic study, treatment modality is a significant predictor of survival, but after the inclusion of the time-dependent low-density lipoprotein cholesterol variable, the precision of the estimate improves from a P value of 0.02 to 0.0001. Predictors of survival …
In a long-term therapeutic study, treatment modality is a significant predictor of survival, but after the inclusion of the time-dependent l …
Clinical trials: specific problems associated with the use of a placebo-control group.
Cleophas TJ. Cleophas TJ. J Mol Med (Berl). 1995 Aug;73(8):421-4. doi: 10.1007/BF00240142. J Mol Med (Berl). 1995. PMID: 8528745
(d) A biased placebo period due to carry-over effect is a common problem of controlled trials with a cross-over or self-controlled design. (e) Likewise an asymmetric placebo group is also a common problem in parallel-group designs. ...
(d) A biased placebo period due to carry-over effect is a common problem of controlled trials with a cross-over or self-controlled design. ( …